{"id":9770,"date":"2004-05-02T19:22:03","date_gmt":"2004-05-02T19:22:03","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9770"},"modified":"2014-05-22T17:23:47","modified_gmt":"2014-05-22T17:23:47","slug":"us-treatment-guidelines-updated-march-2004","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9770","title":{"rendered":"US treatment guidelines updated \u2013 March 2004"},"content":{"rendered":"<p><strong>The US Department of Health and Human Services updated its adult antiretroviral treatment guidelines on 23 March 2004.<\/strong><\/p>\n<p>The following changes have been made to recommended regimens for ARV-na\u00efve patients:<\/p>\n<ul>\n<li>Fosamprenavir and ritonavir-boosted fosamprenavir are added as options for PI-based regimens and amprenavir and unboosted indinavir have been removed<\/li>\n<li>Abacavir plus lamivudine has been added as an alternative 2-NRTI backbone.<\/li>\n<\/ul>\n<p>New safety information regarding the risks of nevirapine-associated symptomatic hepatic events has been added to the text of the guidelines (sections on \u201cNNRTI-Based Regimens\u201d and \u201cHepatotoxicity\u201d) and the respective tables (Tables 12a, 12b, and 19).<\/p>\n<p>Characteristics and drug interaction information for fosamprenavir have been added to the respective tables (Tables 17, 20, 21, 22a, 22b, 23, and 30).<\/p>\n<p>A new table of antiretroviral dosing recommendations for patients with renal or hepatic dysfunction has been created (Table 13).<\/p>\n<p>Link:<br \/>\n<a href=\"http:\/\/aidsinfo.nih.gov\/guidelines\/adult\/AA_032304.html\">http:\/\/aidsinfo.nih.gov\/guidelines\/adult\/AA_032304.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US Department of Health and Human Services updated its adult antiretroviral treatment guidelines on 23 March 2004. The following changes have been made to recommended regimens for ARV-na\u00efve patients: Fosamprenavir and ritonavir-boosted fosamprenavir are added as options for PI-based &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-9770","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9770"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9770\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}